Ocera Therapeutics Inc (NASDAQ:OCRX) Price, message volume and investor sentiment are all peaking for OCRX according to StockTwits. That seems to be the general consensus on Wall St. as well. Three analysts give OCRX a BUY rating and give a price target of $9.33, a whopping 320% above current pricing.
OCRX is trading above its 10 day simple moving average. Traders generally consider this a sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.
Ocera Therapeutics Inc (NASDAQ:OCRX) is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients.
The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Recent news out of Palo Alto, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2016 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (NASDAQ:OCRX), announced completion of enrollment in STOP-ALF, a Phase 2a clinical trial to evaluate the Safety and Tolerability of Ornithine Phenylacetate in patients with Acute Liver Failure. The study was conducted by the Acute Liver Failure Study Group, an NIH-sponsored network of university tertiary care liver transplant sites, with support and supply of study medication from Ocera.
“We are excited to announce the completion of STOP-ALF and to report there were no serious safety issues attributable to study medication observed at any dose level,” said William M. Lee, M.D., principal investigator of the study. “We are currently examining additional safety and tolerability parameters, and pharmacokinetic findings for OCR-002 in these acutely ill patients. A late-breaker abstract of top-line findings has been submitted to the American Association for the Study of Liver Diseases (AASLD) for presentation at “The Liver Meeting®” being held in mid-November.
Acute Liver Failure (ALF) is a rare syndrome with a significant mortality rate affecting an estimated 2,000 previously healthy individuals annually in the U.S. ALF is a rapid deterioration of liver function, often due to acetaminophen and idiosyncratic drug reactions, resulting in the liver’s inability to clear the circulating toxin Ammonia, which can lead to cerebral edema, intracranial hypertension, brainstem herniation and death.
Find out when $OCRX reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
VHCP Management II LLC acquired a new position in shares of Ocera Therapeutics during the first quarter valued at about $2.7M. Deerfield Management Co. boosted its position in shares of Ocera Therapeutics by 660.9% in the second quarter. Deerfield Management Co. now owns 572,893 shares of OCRX stock valued at $1M after buying an additional 497,600 shares during the period. Vivo Capital LLC acquired a new position in shares of Ocera during the first quarter valued at nearly $451,000. Bridgeway Capital Management Inc. boosted its position in shares of Ocera Therapeutics by 55 percent in the 2nd quarter. Bridgeway Capital Management Inc. now owns 210,860 shares of the biopharmaceutical company’s stock valued at $401,000 after buying an additional 75,000 shares during the period.
Finally, Renaissance Technologies LLC boosted its position in shares of Ocera Therapeutics by 39.3% in the first quarter. Renaissance Technologies LLC now owns 146,400 shares of OCRX stock valued at $430K after buying an additional 41,300 shares during the period.
OCRX has been hitting the target on many levels recently. If Ocera can capitalize on the recent string of good news, and hit or beat its earnings mark on November 2, then we could see another uptick from this under-the-radar biopharm stock. For continuing coverage on $OCRX and our other fast moving picks, sign up for our free newsletter today and get our next hot stock pick!